Cargando…

High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy

Approximately 70% of breast cancers (BCs) express estrogen receptor alpha (ERα) and are treated with endocrine therapy. However, the effectiveness of this therapy is limited by innate or acquired resistance in approximately one-third of patients. Activating mutations in the ESR1 gene that encodes ER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lupini, Laura, Moretti, Anna, Bassi, Cristian, Schirone, Alessio, Pedriali, Massimo, Querzoli, Patrizia, Roncarati, Roberta, Frassoldati, Antonio, Negrini, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847549/ https://www.ncbi.nlm.nih.gov/pubmed/29531247 http://dx.doi.org/10.1038/s41598-018-22312-x

Ejemplares similares

miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression
por: Ferracin, Manuela, et al.
Publicado: (2013)

The Importance of microRNAs in RAS Oncogenic Activation in Human Cancer
por: Roncarati, Roberta, et al.
Publicado: (2019)

Metastatic syringoid eccrine carcinoma of the nipple
por: Ballardini, Pierluigi, et al.
Publicado: (2012)

Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with “Oncogene-Addicted” Advanced Lung Adenocarcinoma: A Real-World Clinical Study
por: Lupini, Laura, et al.
Publicado: (2022)

Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR
por: Mangolini, Alessandra, et al.
Publicado: (2015)

Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer
por: Roncarati, Roberta, et al.
Publicado: (2020)

GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature
por: Querzoli, Patrizia, et al.
Publicado: (2021)

Microscopic tumor foci in axillary lymph nodes may reveal the recurrence dynamics of breast cancer
por: Demicheli, Romano, et al.
Publicado: (2019)

Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma
por: Moshiri, Farzaneh, et al.
Publicado: (2018)

Absolute quantification of cell-free microRNAs in cancer patients
por: Ferracin, Manuela, et al.
Publicado: (2015)

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma
por: Drouyer, Aurélien, et al.
Publicado: (2023)

Trop-2 Is a Determinant of Breast Cancer Survival
por: Ambrogi, Federico, et al.
Publicado: (2014)

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models
por: Callegari, Elisa, et al.
Publicado: (2022)

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models
por: Callegari, Elisa, et al.
Publicado: (2022)

ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients
por: Bos, Manouk K., et al.
Publicado: (2022)

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
por: Hartmaier, R J, et al.
Publicado: (2018)

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients
por: Lupini, Laura, et al.
Publicado: (2015)

Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy
por: Levati, Lauretta, et al.
Publicado: (2022)

ESR1 NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of ESR1 Mutations in Liquid Biopsies
por: Stergiopoulou, Dimitra, et al.
Publicado: (2021)

The ESR Patient Advisory Group (ESR-PAG)
Publicado: (2015)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment
por: Dessources, Kimberly, et al.
Publicado: (2022)

Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis
por: Dika, Emi, et al.
Publicado: (2021)

XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation
por: Barua, David, et al.
Publicado: (2020)

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
por: Martin, Lesley-Ann, et al.
Publicado: (2017)

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
por: Li, Li, et al.
Publicado: (2020)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

ESR1 and ESR2 genotypes and the age at menarche in idiopathic scoliosis
por: Janusz, Piotr, et al.
Publicado: (2014)

Stochastic Cooling at the ESR
por: Beckert, Karl, et al.
Publicado: (2000)

Stochastic cooling at the ESR
por: Beckert, K, et al.
Publicado: (1999)

The predictive ability of plasma ESR1 mutations for the efficacy of endocrine therapy in hormone-receptor-positive advanced breast cancer
por: Du, Yangfan, et al.
Publicado: (2018)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2021)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

A circulating miRNA assay as a first-line test for prostate cancer screening
por: Sharova, Evgeniya, et al.
Publicado: (2016)

miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs
por: Lupini, Laura, et al.
Publicado: (2013)

Currently Applied Molecular Assays for Identifying ESR1 Mutations in Patients with Advanced Breast Cancer
por: Lee, Nuri, et al.
Publicado: (2020)

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n34ng3k5e30v9dq8up0rf6vn10